The patent, entitled ‘Skin Permeation Device For Analyte Sensing or Transdermal Drug Delivery’, covers the Prelude SkinPrep system and its typical method of use for preparing the skin in a controlled, dermabrasive manner to allow for either analyte extraction or drug delivery.
The USPTO, which has initially calculated the patent term expiry as 2030, said the patent may be entitled to additional patent term due to delays by the organization and may expire at a later date.
Echo Therapeutics chairman and chief executive officer Patrick Mooney said the patent is critical to the company’s intellectual property strategy for protecting its position in non-invasive continuous glucose monitoring and transdermal drug delivery markets worldwide.
"Furthermore, this U.S. patent issuance serves again to strengthen Echo’s already formidable intellectual property estate," Mooney added.
